Misplaced Pages

Revision as of 08:04, 1 November 2011

Idursulfase (brand name Elaprase) is a drug used to treat Hunter syndrome (also called Mucopolysaccharoidosis II). It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

It is one of the most expensive drugs ever produced, costing $375,000 per year.

It is manufactured by Shire Pharmaceuticals Group.

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.{{cite journal}}: CS1 maint: multiple names: authors list (link)
3. "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29.
4. Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010

External links

• idursulfase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Orphan drugs
• Gastrointestinal system drug stubs